Allen C Gao
Affiliation: University of California
Nadiminty N, Tummala R, Liu C, Lou W, Evans C, Gao A. NF-ÎºB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer. Mol Cancer Ther. 2015;14:1884-95 pubmed publisher
..These findings may provide a rationale for cotargeting these pathways to achieve better efficacy through AR blockade. ..
Qu S, Wang K, Xue H, Wang Y, Wu R, Liu C, et al
. Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient-derived, advanced prostate cancer tissue xenograft model. Mol Oncol. 2014;8:311-22 pubmed publisher
..Our findings, obtained with a highly clinically relevant prostate cancer model, suggest, for the first time, that docetaxel-based therapy of advanced human prostate cancer may be improved by combining docetaxel with Aneustat. ..
Liu C, Lou W, Zhu Y, Yang J, Nadiminty N, Gaikwad N, et al
. Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer. Cancer Res. 2015;75:1413-22 pubmed publisher
Zhu Y, Liu C, Armstrong C, Lou W, Sandher A, Gao A. Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer. Clin Cancer Res. 2015;21:4133-42 pubmed publisher
..These studies may lead to the development of combinational therapies with bicalutamide/enzalutamide and docetaxel as effective regimens to treat advanced prostate cancer independent of AR status, and possibly other types of cancer. ..
Gao A, Zhu Y. Stat5a/b in Prostate Cancer Metastasis. Am J Pathol. 2015;185:2351-3 pubmed publisher
..This commentary highlights the article by Talati etÂ al that describes novel mechanisms promoting metastasis in prostate cancer. ..
Lombard A, Liu L, Cucchiara V, Liu C, Armstrong C, Zhao R, et al
. Intra vs Inter Cross-Resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer. Mol Cancer Ther. 2018;: pubmed publisher
..Additionally, the development and use of biomarkers indicating resistance will improve patient stratification for treatment. ..
Liu C, Armstrong C, Lou W, Lombard A, Evans C, Gao A. Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer. Mol Cancer Ther. 2017;16:35-44 pubmed publisher
..Mol Cancer Ther; 16(1); 35-44. Â©2016 AACR. ..
Zhu Y, Liu C, Nadiminty N, Lou W, Tummala R, Evans C, et al
. Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer. Mol Cancer Ther. 2013;12:1829-36 pubmed publisher
Chandrasekar T, Yang J, Gao A, Evans C. Targeting molecular resistance in castration-resistant prostate cancer. BMC Med. 2015;13:206 pubmed publisher
..We review current knowledge of mechanisms of resistance to the currently approved treatments, development of adjunctive therapies, and identification of new pathways being targeted for therapeutic purposes. ..